Articles On Oncosil Medical (ASX:OSL)

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

The OncoSil Medical Ltd (ASX: OSL) share price is soaring higher on Friday after the company announced the publication of the PanCO clinical study’s final results. The study confirmed the company’s OncoSil device can be safely and successf...

OncoSil Medical (OSL) publishes the final results of the PanCO clinical study for its OncoSil device OncoSil is a targeted radioactive isotope implanted directly into a patient’s pancreatic tumours via an endoscopic ultrasound No radiation...

The ASX 200 Health Index (XHJ) is trading higher by 0.70% at the time of writing, compared to the broader index which is up by 0.55%. OncoSil Medical (ASX:OSL) has released the final results of the PanCO clinical study for the treatment of...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

As the world emerges from the pandemic, markets are now contending with an energy crisis, a global shipping glut and the prospect of central banks starting to raise interest rates. But so far this week, investors are shrugging it all off as...

OncoSil Medical (ASX:OSL) has announced the appointment of Professor Ricky Sharma to its board as a non-executive director.

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

Summary The S&P/ASX200 ended lower by just 10 basis points at 7,394.30, shedding early gains. The index gained 0.3% to hit an all-time high of 7,417.60 during the day’s trade. Material sector emerged as the best performer, settlin...

The ASX clawed back initial gains to start the week, closing virtually flat today. The ASX 200 closed at 7,394 which was neck and neck with the point it closed at on Friday despite gaining as much as 0.3% in early trade. Meanwhile, the ASX...

Summary The ASX 200 has continued its momentum in the opening session, making a record high. All three major US stock indices also closed at an all-time high on Friday after a volatile week. Metals X Limited is planning to recommence...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

It was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies releasing seperate announcements that sent their share prices higher. Cancer therapy stocks Invion (ASX:IVX), Immutep (ASX:IMM), and Imugene (ASX...

The Oncosil Medical Ltd (ASX: OSL) share price finished in positive territory during late-afternoon trade. This comes after the company announced it has received regulatory approval from an important strategic market. At market close, the...

On a day the ASX finished nearly 0.5 per cent up, tech stood alone in the red losing more than 2 per cent. The ASX 200 closed 0.56 per cent up at 7,068 points and the ASX Emerging Companies Index rose 0.41 per cent closing at 2,111 points....

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

22 Jan 2021 - Medical device company, OncoSil Medical (ASX:OSL) has appointed Nigel Lange as Chief Executive Officer and Managing Director.

The Oncosil Medical Ltd (ASX: OSL) share price jumped 10% on Thursday after the company received regulatory clearance to market and sell its products in Switzerland.  About Oncosil  Oncosil is focused on localised treatments for patients w...

The coronavirus pandemic has rocked almost every economy around the world, and Australia's is no exception. Although Australia has done a relatively decent job containing the spread of the virus when compared to other countries, it hasn’t b...

ShareCafeOncosil Medical – ShareCafe Hidden Gems Webinar Presentation   Presenter – Daniel Kenny – CEO – OncoSil Medical is a medical device company seeking to advance radiation for cancer patients. OncoSil Medical’s lead product, OncoSilT...

ShareCafeHidden Gems Webinar Recap – OSL, MDC, CYP, GSS   We continue to unearth small-cap companies as part of our Hidden Gems webinar series. Catch up on the full webinar with presentations from Oncosil Medical (ASX:OSL), Medlab Clinical...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The pundit...

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the pen and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim catches up with Daniel Kenny, Chief Executive Officer at...

In the past fortnight there were over 30 directors trades of $100,000 or more among ASX small cap directors. The list included multiple groups of directors. Five directors from water treatment stock Phoslock (ASX:PET) put in $1.3m between t...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Now invest...

Want to know which stocks the fund managers have been putting their money in (and out) of? We’ve been keeping track so you don’t have to. Trading Places is Stockhead’s recap of substantial holder movements among ASX small caps in the last f...

OncoSil Medical (ASX:OSL) has received CE Mark approval to market and sell its breakthrough implantable radiotherapy treatment for pancreatic cancer in the EU and UK.

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   This week’s big themes The ca...

Medical device company OncoSil Medical (ASX: OSL) has announced that it has finally received the CE Mark from the British Standards Institute (BSI) for its proprietary OncoSil device – a means of treating locally advanced pancreatic cancer...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

OncoSil Medical Ltd (ASX:OSL) has received CE Marking approval from the British Standards Institute (BSI) for its OncoSilTM device used in the treatment of locally advanced pancreatic cancer (LAPC) in combination with chemotherapy. OncoSilT...

OncoSil Medical Ltd (ASX:OSL) has received CE Marking approval from the British Standards Institute (BSI) for its OncoSilTM device used in the treatment of locally advanced pancreatic cancer (LAPC) in combination with chemotherapy. OncoSilT...

Medical device company OncoSil Medical (ASX: OSL) has been granted what’s known as breakthrough device designation by the US Food and Drug Administration (FDA) for the treatment of pancreatic cancer in combination with systemic chemotherapy...

Medical device company OncoSil Medical (ASX: OSL) has been granted what’s known as breakthrough device designation by the US Food and Drug Administration (FDA) for the treatment of pancreatic cancer in combination with systemic chemotherapy...

OncoSil Medical Ltd (ASX:OSL) today announced that the OncoSilTM device has reached a significant milestone, receiving Breakthrough Device Designation by the US Food and Drug Administration (FDA) for the treatment of unresectable locally ad...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

OncoSil Medical (ASX: OSL) has developed a first-in-class, truly innovative device that treats unresectable locally advanced pancreatic cancer — that is, tumours that can’t be surgically removed.

The health sector was the most successful sector on the ASX in 2019. Various small caps made several breakthroughs including with nerve damage and macular degeneration. While cancer remains one fish that has yet to be fried there are small...

The coming 12 months is shaping up as a watershed stage in the history of Oncosil Medical Ltd (ASX:OSL) with the company having flagged finalisation of commercialisation plans for its OncoSilTM device in anticipation of CE Marking early in...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Medical devices are considered as an essential part of the health care industry and range from a bandage to high-risk products for implanting in the human body such as pacemakers. Medical devices differ from the general medicines as they ar...